System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish 2 citations

PubMed: 39288961 DOI: 10.1136/jnnp-2024-333819

Neuropsychiatric symptoms in cognitive decline and Alzheimer's disease: biomarker discovery using plasma proteomics.

J Neurol Neurosurg Psychiatry 96(4):370-382

Authors: Miriam Rabl, Christopher Clark, Loïc Dayon, Julius Popp

Affiliations

  • Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich, Psychiatric University Hospital, Zurich, Switzerland.
  • Nestlé Institute of Food Safety & Analytical Sciences, Nestlé Research, Lausanne, Switzerland.
  • Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland.
  • Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich, Psychiatric University Hospital, Zurich, Switzerland.
  • Old-Age Psychiatry Service, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland.

Abstract

BACKGROUND AND OBJECTIVES

Neuropsychiatric symptoms (NPS) are common in older people with cognitive impairment and Alzheimer's disease (AD). No biomarkers to detect the related pathology or predict the clinical evolution of NPS are available yet. This study aimed to identify plasma proteins that may serve as biomarkers for NPS and NPS-related clinical disease progression.

METHODS

A panel of 190 plasma proteins was quantified using Luminex xMAP in the Alzheimer's Disease Neuroimaging Initiative cohort. NPS and cognitive performance were assessed at baseline and after 1 and 2 years. Logistic regression, receiver operating characteristic analysis and cross-validation were used to address the relations of interest.

RESULTS

A total of 507 participants with mild cognitive impairment (n=396) or mild AD dementia (n=111) were considered. Selected plasma proteins improved the prediction of NPS (area under the curve (AUC) from 0.61 to 0.76, p<0.001) and future NPS (AUC from 0.63 to 0.80, p<0.001) when added to a reference model. Distinct protein panels were identified for single symptoms. Among the selected proteins, ANGT, CCL1 and IL3 were associated with NPS at all three time points while CCL1, serum glutamic oxaloacetic transaminase and complement factor H were also associated with cognitive decline. The associations were independent of the presence of cerebral AD pathology as assessed using cerebrospinal fluid biomarkers.

CONCLUSIONS

Plasma proteins are associated with NPS and improve prediction of future NPS.

MeSH

Alzheimer Disease, Pathology, Cognitive Dysfunction, Biomarkers, Signs And Symptoms, Complement Factor H, Cognition Disorders, Proteomics, Neurology, Plasma

Cited by